View profile

FarmaKology -New drug offers hope for pancreatic cancer patients



November 11 · Issue #87 · View online

FarmaKology is a newsletter that brings you the latest news, research, job opportunities in the Pharma world, and much more! If you would like to be featured in the newsletter, sponsor an issue, or need anything, please feel free to get in touch with me at "".

Would you like to submit an article, some interesting news, or get your startup featured? Send whatever you have to, and happy to have you featured on our newsletter (+13K Subscribers )!

Novo Banking
Novo Banking
Today's Company
Arbor Biotechnologies
Arbor Biotechnologies
Arbor Biotechnologies
Arbor Biotechnologies is an early stage life sciences company pushing the boundaries of biodiscovery. Arbor’s platform employs a diverse set of technologies and techniques – including artificial intelligence, genome sequencing, gene synthesis and high-throughput screening – for accelerating the discovery of proteins for improving human health and sustainability.
Merck , known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced that the Japanese government will purchase, upon authorization or approval, approximately 1.6 million courses of molnupiravir (MK-4482, EIDD-2801), an investigational oral antiviral medicine. Merck is developing molnupiravir in collaboration with Ridgeback Biotherapeutics. Merck’s applications for the potential authorized use of molnupiravir are under review by Japan’s Pharmaceuticals and Medical Devices Agency, the U.S. Food and Drug Administration, and the European Medicines Agency. Molnupiravir is authorized in the United Kingdom for the treatment of mild-to-moderate COVID-19 in adults with a positive SARS-CoV-2 diagnostic test and who have at least one risk factor for developing severe illness.
Notable Labs, Inc. , a pioneer and developer of predictive precision medicines, has obtained worldwide rights to volasertib from Oncoheroes Biosciences Inc., a Boston-based biotechnology company focused on advancing new therapies for childhood cancer. Volasertib is a Polo-like kinase 1 (PLK-1) inhibitor with demonstrated activity in acute myeloid leukemia (AML) and other tumor types with significant unmet medical need.
Novo Nordisk today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion, recommending marketing authorisation for Wegovy™ for chronic weight management in adults with obesity.Wegovy™ is a once-weekly semaglutide 2.4 mg injection for chronic weight management in adults living with obesity (initial BMI≥30 kg/m2) or overweight (initial BMI≥27 kg/m2) with at least one weight-related comorbidity such as high blood pressure, heart disease or type 2 diabetes.
AffaMed Therapeutics , a global clinical-stage therapeutic company dedicated to developing and commercializing transformative pharmaceutical, digital and surgical products that address critical unmet medical needs in ophthalmic, neurological and psychiatric disorders, today announced the establishment of AffaMed Digital. As a wholly owned subsidiary of AffaMed, the new AffaMed Digital will focus on the development and commercialization of evidence-based, clinically validated digital medicines to treat, diagnose, prevent, and/or manage medical disorders or diseases, either as stand-alone novel treatment options, or in concert with other therapies to optimize patient care and health outcomes.
Spend $1 Today, Save up to $2k on Your Next Vacay with Dollar Flight Club.
Research & Study
Stream episode Episode 39: A patient and a nephrologist on how using race in kidney testing puts lives at risk by First Opinion Podcast podcast | Listen online for free on SoundCloud
Job Opportunities
Upcoming Webinar
The Technological Future Of Pharma - Live Q&A with The Medical Futurist
Did you enjoy this issue?
In order to unsubscribe, click here.
If you were forwarded this newsletter and you like it, you can subscribe here.
Powered by Revue